Holen Sie sich die Stockscreener-App
8.93
10.25%
0.83
Handel nachbörslich:
8.55
-0.38
-4.26%
Schlusskurs vom Vortag:
$8.10
Offen:
$8.24
24-Stunden-Volumen:
1.06M
Relative Volume:
1.17
Marktkapitalisierung:
$451.09M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.6977
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+8.51%
1M Leistung:
+2.88%
6M Leistung:
+21.99%
1J Leistung:
-27.46%
1-Tages-Spanne:
$8.225
$9.245
1-Wochen-Bereich:
$7.35
$9.245
52-Wochen-Spanne:
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.93 | 409.17M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Are Options Traders Betting on a Big Move in Regenxbio Stock? - TradingView
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
When is the best time to exit REGENXBIO Inc.Breakout Screener With Alert Based Timing - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Raymond James Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Can REGENXBIO Inc. hit a new high this monthPredictable Entry Strategy With Technical Backing - Newser
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com Australia
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk - MarketScreener
Regenxbio: Chardan Capital maintains Buy, PT raised to $52 from $52. - AInvest
Transcript : REGENXBIO Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Regenxbio 2025 Q2 Earnings Wider Losses Amid Progress in Gene Therapy Pipeline - AInvest
Regenxbio Inc (RGNX) Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... By GuruFocus - Investing.com Canada
REGENXBIO Reports Q2 2025 Financial Results and Progress - TipRanks
Forecasting REGENXBIO Inc. price range with options dataExit Strategy Guide With Risk Control Plan - Newser
Regenxbio Inc. shares rise 1.27% after-hours following the initiation of a pivotal Phase IIb/III clinical trial for diabetic retinopathy. - AInvest
Regenxbio: Q2 Earnings Snapshot - The Washington Post
Regenxbio stock maintains Outperform rating at Raymond James on solid cash runway - Investing.com Nigeria
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips - Investing.com
Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips By Investing.com - Investing.com Canada
Regenxbio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
XtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal - Endpoints News
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy - TipRanks
Regenxbio Incphase IIb/III trial to be initiated for diabetic retinopathy - MarketScreener
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
RegenXBio and AbbVie Amend Collaboration Agreement - TipRanks
Regenxbio Inc earnings missed by $0.44, revenue fell short of estimates - Investing.com South Africa
Biotech firm Regenxbio Q2 net loss widens - MarketScreener
REGENXBIO to advance diabetic retinopathy treatment to Phase IIb/III trial By Investing.com - Investing.com Australia
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights - Yahoo Finance
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy - Yahoo Finance
Analyzing drawdowns of REGENXBIO Inc. with statistical toolsLong-Term Safety Investment Analysis Report - Newser
Options Data Show Bullish Bias in REGENXBIO Inc.Free Stock Market Strategy Classes - beatles.ru
REGENXBIO Inc. Stock Analysis and ForecastAchieve breakthrough performance with smart picks - Jammu Links News
What catalysts could drive REGENXBIO Inc. stock higher in 2025Get alerts on top growth stocks daily - Jammu Links News
What is the dividend policy of REGENXBIO Inc. stockSkyrocketing investment returns - Jammu Links News
How many analysts rate REGENXBIO Inc. as a “Buy”Phenomenal returns - Jammu Links News
What is REGENXBIO Inc. company’s growth strategyAchieve consistent profits with smart trading - Jammu Links News
How strong is REGENXBIO Inc. company’s balance sheetExceptional ROI - Jammu Links News
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):